SCOPUS
Farmakoekonomika
IRBIS LLC, Russian Federation
Farmakoekonomika is an academic journal published by IRBIS LLC (Russian Federation). Identifiers: ISSN 2070-4909, eISSN 2070-4933. Indexed in SCOPUS. Metrics: CiteScore 1.2, SJR 0.143, SNIP 0.25. tlooto lists 107 papers from this journal.
CiteScore
1.20
Scopus citation metric
SJR
0.143
SCImago rank
SNIP
0.25
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 2070-4909
- eISSN
- 2070-4933
- Abbreviation
- -
- Publisher
- IRBIS LLC
- Country
- Russian Federation
Web of Science categories
No Web of Science category data available.
Scopus ASJC categories
2719 Health Policy2739 Public Health3004 Pharmacology
Papers in this journal
Recent papers
- Chemoreactomic analysis of magnesium- and vitamin B6-depleting drugs within the Anatomical Therapeutic Chemical classification as a basis for preventing adverse effects of pharmacotherapy
2026
- Computer-based systematic analysis of fundamental and clinical studies on the pharmacology of alloferon
2026
- Pharmacoeconomic and socioeconomic aspects of multiple sclerosis treatment in different countries
2026
- A method for evaluating diagnostic effectiveness using algorithms based on opinion obtained from artificial intelligence models
2026 · 1 citations
- Studying the risks of drug provision for breast cancer patients in the public procurement system of Russia
2026
Most cited papers
- Effectiveness of preliminary differential diagnosis of benign and malignant skin neoplasms using the Derma Onko Check artificial intelligence program
2025 · 13 citations
- Current approaches to the treatment of vulvovaginal atrophy in women with gynecological and breast cancer
2025 · 5 citations
- Artificial intelligence in oncology: global experience and future prospects
2025 · 4 citations
- Artificial intelligence in dermatology: a comparative analysis of computer vision programs based on machine learning models
2026 · 4 citations
- Results of the survey of experts on the need to incorporate real-world evidence to the comprehensive drug assessment
2025 · 4 citations